Evidence map›Paper›PMID 29250863›Full record

ArticleChemistry (Weinheim an der Bergstrasse, Germany)2018

Cyclobutanone Mimics of Intermediates in Metallo-β-Lactamase Catalysis.

Martine I Abboud, Magda Kosmopoulou, Anthony P Krismanich, Jarrod W Johnson, Philip Hinchliffe, Jürgen Brem, Timothy D W Claridge, James Spencer, Christopher J Schofield, Gary I Dmitrienko

Open access · hybridAbstract read
In one paragraph

Article in Chemistry (Weinheim an der Bergstrasse, Germany), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.3field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Will morphing boron-based inhibitors beat the β-lactamases?Current opinion in chemical biology · 2019
    Review
  11. Review
  12. Review
  13. Cyclobutanone Mimics of Intermediates in Metallo-β-Lactamase Catalysis.Chemistry (Weinheim an der Bergstrasse, Germany) · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 3 countries.

Martine I AbboudDepartment of Chemistry, University of Oxford, 12 Mansfield Road, Oxford, OX1 3TA, UK.ORCID http://orcid.org/0000-0003-2141-5988
Magda KosmopoulouSchool of Cellular and Molecular Medicine, University of Bristol, Medical Sciences Building, Bristol, BS8 1TD, UK.
Anthony P KrismanichDepartment of Chemistry, University of Waterloo, 200 University Ave. W., Waterloo, Ontario, N2L 3G1, Canada.
Jarrod W JohnsonDepartment of Chemistry, University of Waterloo, 200 University Ave. W., Waterloo, Ontario, N2L 3G1, Canada.ORCID http://orcid.org/0000-0002-1214-6862
Philip HinchliffeSchool of Cellular and Molecular Medicine, University of Bristol, Medical Sciences Building, Bristol, BS8 1TD, UK.
Jürgen BremDepartment of Chemistry, University of Oxford, 12 Mansfield Road, Oxford, OX1 3TA, UK.ORCID http://orcid.org/0000-0002-0137-3226
Timothy D W ClaridgeDepartment of Chemistry, University of Oxford, 12 Mansfield Road, Oxford, OX1 3TA, UK.ORCID http://orcid.org/0000-0001-5583-6460
James SpencerSchool of Cellular and Molecular Medicine, University of Bristol, Medical Sciences Building, Bristol, BS8 1TD, UK.
Christopher J SchofieldDepartment of Chemistry, University of Oxford, 12 Mansfield Road, Oxford, OX1 3TA, UK.ORCID http://orcid.org/0000-0002-0290-6565
Gary I DmitrienkoDepartment of Chemistry, University of Waterloo, 200 University Ave. W., Waterloo, Ontario, N2L 3G1, Canada.
Mansfield University · USUniversity of Bristol · GBUniversity of Waterloo · CA

Funding

A Mechanism-Based Approach to Metallo-beta-Lactamase InhibitionR01AI100560 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A., SPENCER, JAMES · 2012 to 2022
$4.4M
Medical Research Council G1100135Medical Research Council MC_PC_14103Medical Research Council MR/L007665/1NIAID NIH HHS R01 AI100560Wellcome Trust
6 · The paper itself

Abstract

The most important resistance mechanism to β-lactam antibiotics involves hydrolysis by two β-lactamase categories: the nucleophilic serine and the metallo-β-lactamases (SBLs and MBLs, respectively). Cyclobutanones are hydrolytically stable β-lactam analogues with potential to inhibit both SBLs and MBLs. We describe solution and crystallographic studies on the interaction of a cyclobutanone penem analogue with the clinically important MBL SPM-1. NMR experiments using

Indexed as

beta-Lactamase Inhibitorsbeta-Lactamasesbeta-LactamsCatalysisCyclobutanesMeropenemMolecular MimicryNuclear Magnetic Resonance, BiomolecularThienamycinsbeta-Lactamase Inhibitorsbeta-Lactamasesbeta-LactamsCyclobutanesMeropenemThienamycinsantimicrobial resistancecyclobutanonestransition state analoguesβ-lactam analoguesβ-lactamases

Identifiers

PMID29250863
PMCPMC5947706
OpenAlexW2772800318

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.